Quarterly report · Q3

Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥179.2bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥63.4bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥175.2bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥62.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥55.0bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥20.4bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥58.7bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥22.4bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥57.3bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥20.0bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥60.2bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.2bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥36.6bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥13.2bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥39.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥38.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥13.8bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥41.8bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥15.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥463.8bnat 2023-12-31Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥380.7bnat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥112.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥351.1bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥297.4bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥337.1bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥290.7bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥143.1bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥109.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥35.6bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥33.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥26.3bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.6bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥13.9bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.7bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥53.932023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.452023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥57.862022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.422022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥53.892023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.442023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥57.822022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.42022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio72.7%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio76.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥2.6bn
Reconciling Itemsreconcilingrevenue2023-10-01 → 2023-12-31−¥779m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥2.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-10-01 → 2023-12-31−¥779m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥459m
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2023-12-31−¥584m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥12.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥3.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥12.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥3.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥31m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥10m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥3.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥549m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥20.3bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥6.5bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥248m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥32m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥1.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-12-31¥71.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2023-10-01 → 2023-12-31¥26.0bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-12-31¥69.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2023-10-01 → 2023-12-31¥25.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥2.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥710m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-12-31¥30.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2023-10-01 → 2023-12-31¥11.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-12-31¥52.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2023-10-01 → 2023-12-31¥19.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-12-31¥52.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2023-10-01 → 2023-12-31¥19.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥15m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥4m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-12-31¥12.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2023-10-01 → 2023-12-31¥5.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥23.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥23.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥10m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥3m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥2.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥842m
—segment totalrevenue2023-04-01 → 2023-12-31¥179.8bn
—segment totalrevenue2023-10-01 → 2023-12-31¥63.4bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥177.3bn
—segment totalrevenue external2023-10-01 → 2023-12-31¥62.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥2.5bn
—segment totalrevenue intersegment2023-10-01 → 2023-12-31¥759m
—segment totalsegment profit2023-04-01 → 2023-12-31¥54.9bn
—segment totalsegment profit2023-10-01 → 2023-12-31¥20.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥418m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥11.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥3.1bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥10.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥2.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥623m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥178m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥4.2bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥734m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥6.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥521m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥174m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.0bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-12-31¥69.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-10-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-12-31¥67.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-10-01 → 2022-12-31¥26.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥739m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-12-31¥32.1bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-10-01 → 2022-12-31¥13.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-12-31¥47.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-12-31¥47.2bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥21m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-12-31¥13.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-10-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥27.5bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥304m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥3.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥917m
—segment totalrevenue2022-04-01 → 2022-12-31¥176.6bn
—segment totalrevenue2022-10-01 → 2022-12-31¥62.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥172.8bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥61.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥3.8bn
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥1.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥59.5bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥22.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 773
ItemContextValueUnit
Fund name in japaneseFilingDateInstant-
Fund name in englishFilingDateInstant-
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant-
Current fiscal year start dateFilingDateInstant2023-04-01
Current period end dateFilingDateInstant2023-12-31
Type of current periodFilingDateInstantQ3
Current fiscal year end dateFilingDateInstant2024-03-31
Previous fiscal year start dateFilingDateInstant2022-04-01
Comparative period end dateFilingDateInstant2022-12-31
Previous fiscal year end dateFilingDateInstant2023-03-31
Next fiscal year start dateFilingDateInstant-
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant-
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant-
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所プライム市場
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)単元株式数100株
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Voting rights (text)FilingDateInstantText · Plus
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsOtherMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesLessThanOneUnitMember-
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)エムスリー株式会社
Address of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)東京都港区赤坂一丁目11番44号
Information about officers (text)FilingDateInstantText · Plus
Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial informationCurrentYTDDurationText · Plus
Note on independent audit financial informationCurrentYTDDurationText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass